MALIGNANT-MELANOMA - STAGING WITH WHOLE-BODY POSITRON EMISSION TOMOGRAPHY AND 2-[F-18]-FLUORO-2-DEOXY-D-GLUCOSE

被引:165
作者
STEINERT, HC
BONI, RAH
BUCK, A
BONI, R
BERTHOLD, T
MARINCEK, B
BURG, G
VONSCHULTHESS, GK
机构
[1] UNIV ZURICH HOSP,DIV DIAGNOST RADIOL,CH-8091 ZURICH,SWITZERLAND
[2] UNIV ZURICH HOSP,DEPT DERMATOL,CH-8091 ZURICH,SWITZERLAND
关键词
EMISSION CT (ECT); GLUCOSE; MELANOMA; NEOPLASMS; STAGING;
D O I
10.1148/radiology.195.3.7753998
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To evaluate whole-body positron emission tomography (PET) with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) in the detection of metastasis from melanoma. MATERIALS AND METHODS: Whole-body PET was performed in 33 patients with either known metastatic or newly diagnosed melanoma. Patients with suspected metastases also underwent computed tomography, magnetic resonance imaging, or both. Diagnoses were confirmed with histologic examination or with at least one imaging modality in addition to PET. Blinded interpretations of PET scans were performed. RESULTS: Forty of 53 lesions evaluated proved to be melanoma metastases. Whole-body PET correctly depicted 37 sites of metastases. Three cutaneous metastases (<3 mm) were missed. PET correctly excluded malignancy in 10 cases where suspicious lesions were found with conventional cross-sectional imaging modalities but later ruled out with fine-needle biopsy. In six patients, PET depicted new metastases. The sensitivity for the detection of malignant lesions was 92%; the specificity for reading the PET images without clinical information was 77% and with clinical information was 100%. CONCLUSIONS: These results suggest that whole-body FDG PET is an effective imaging modality to screen for metastases from malignant melanoma.
引用
收藏
页码:705 / 709
页数:5
相关论文
共 31 条
  • [1] Skolnick A.A., Melanoma epidemic yields grim statistics, JAMA, 265, pp. 3217-3218, (1991)
  • [2] Horgan K., Hughes L.E., Review: Staging of melanoma, Clin Radiol, 48, pp. 297-300, (1993)
  • [3] Buzaid A.C., Sandler A.B., Maani S., Et al., Role of computed tomography in the staging of primary melanoma, J Clin Oncol, 11, pp. 638-643, (1993)
  • [4] Haubold-Reuter B.G., Duewell S., Schilcher B.R., Marincek B., Von Schulthess G.K., The value of bone scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: A prospective study, Eur J Nucl Med, 20, pp. 1063-1069, (1993)
  • [5] Kagan R., Witt T., Bines S., Mesleh G., Economou S., Gallium-67 scanning for malignant melanoma, Cancer, 20, pp. 417-499, (1988)
  • [6] Divigi C.R., Larson S.M., Radiolabelled monoclonal antibodies in the diagnosis and treatment of malignant melanoma, Semin Nucl Med, 19, pp. 252-261, (1989)
  • [7] Jaffe R.M., Alderson P.O., Seldin D.W., Et al., Evaluation of metastatic melanoma with planar and SPECT scintigraphy using ZME 018 and 96.5 radiolabeled monoclonal antibodies, Cancer Detect Prev, 79, pp. 303-312, (1988)
  • [8] Warburg O., The Metabolism of Tumors, pp. 167-181, (1931)
  • [9] Hatanaka M., Transport of sugars in tumor cell membranes, Biochem Biophys Acta, 355, pp. 77-104, (1974)
  • [10] Weber G., Enzymology of cancer cells. II, N Engl J Med, 296, pp. 541-555, (1977)